Nxera Pharma Receives $8.6M Milestone From Eli Lilly Subsidiary Centessa on OX2R Agonist
Question
Nxera Pharma Receives $8.6M Milestone From Eli Lilly Subsidiary Centessa on OX2R Agonist
Direct answer
Nxera Pharma announced receipt of an $8.6 million milestone payment from Centessa Pharmaceuticals, an Eli Lilly subsidiary, following late-stage development advancements for selective orexin receptor 2 (OX2R) agonist candidates. The milestone will be booked as Q3 2026 revenue. The progress underscores ongoing pharmaceutical interest and clinical advancement in next-generation sleep disorder and neurological indications targeting the orexin pathway. — bullish pressure on LLY.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-03
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Nxera Pharma Receives $8.6M Milestone From Eli Lilly Subsidiary Centessa on OX2R Agonist”, revision 1, evidence through 2026-09-03. https://marketontology.com/catalysts/2026-09-03/nxera-pharma-receives-8-6m-milestone-from-eli-lilly-subsidiary-centessa-on-ox2r-f9d414
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| LLY | ▲Bull | 1–3 months | Policy Shift | 74 |
Nxera Pharma Receives $8.6M Milestone From Eli Lilly Subsidiary Centessa on OX2R Agonist
Nxera Pharma announced receipt of an $8.6 million milestone payment from Centessa Pharmaceuticals, an Eli Lilly subsidiary, following late-stage development advancements for selective orexin receptor 2 (OX2R) agonist candidates. The milestone will be booked as Q3 2026 revenue. The progress underscores ongoing pharmaceutical interest and clinical advancement in next-generation sleep disorder and neurological indications targeting the orexin pathway. — bullish pressure on LLY.
Nxera Pharma announced receipt of an $8.6 million milestone payment from Centessa Pharmaceuticals, an Eli Lilly subsidiary, following late-stage development advancements for selective orexin receptor 2 (OX2R) agonist candidates. The milestone will be booked as Q3 2026 revenue. The progress underscores ongoing pharmaceutical interest and clinical advancement in next-generation sleep disorder and neurological indications targeting the orexin pathway.
- SummaryNxera Pharma announced receipt of an $8.6 million milestone payment from Centessa Pharmaceuticals, an Eli Lilly subsidiary, following late-stage development advancements for selective orexin receptor 2 (OX2R) agonist candidates. The milestone will be booked as Q3 2026 revenue. The progress underscores ongoing pharmaceutical interest and clinical advancement in next-generation sleep disorder and neurological indications targeting the orexin pathway.
- LLYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- LLY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- LLY price vs. pre-event level
- LLY volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-19Viking raises $575 million to fund obesity pipeline trialsLLY VKTX
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking Therapeutics Raises $575M in Equity and Convertibles for Phase 3 TrialsLLY VKTX
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking raises $575 million to fund obesity trials through 2028LLY NVO VKTX
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-19Viking financing keeps obesity trial runway open through 2028LLY VKTX
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.